Oxford PharmaGenesis sponsors global HIFA-WHO consultation to promote reliable healthcare information
09 November 2023
Share this page
Oxford PharmaGenesis is proud to sponsor a global consultation, run by Healthcare Information For All (HIFA) in partnership with the World Health Organization (WHO), to accelerate progress towards universal access to reliable healthcare information.
Every day, tens of thousands of children and adults die needlessly for want of simple, low-cost interventions, which are often locally available but not provided in time. A major contributing factor is that the parent, carer or healthcare worker does not have access to the information they need, when they need it, to take appropriate action.
In response, HIFA, a global social movement to improve the availability and use of reliable healthcare information and protect people from misinformation, is collaborating with the WHO on a global consultation. HIFA is administered by Global Healthcare Information Network CIC, a UK-based non-profit in official relations with the WHO since 2022.
The consultation aims to demonstrate public support for the goal of universal access to reliable healthcare information, and to inform action by the WHO and partners in 2024 and beyond.
Reliable healthcare information saves lives
HIFA and the WHO are consulting stakeholders from across the global evidence ecosystem (e.g. healthcare workers, patients, researchers, publishers, policymakers, library and information professionals) to identify challenges, best practices and opportunities to achieve universal access.
The consultation aims to demonstrate widespread support and solidarity for the goal of universal access – critical to securing the high-level political and financial commitments that are needed.
Launched in August this year, and continuing until the end of 2023, the consultation includes:
- a public online global survey
- thematic discussion on the HIFA forums in four languages
- virtual and in-person events
- key informant interviews.
The consultation will be finalized through a seminal report for the WHO.
Open Pharma: a shared objective
Oxford PharmaGenesis CEO Chris Winchester said:
“Oxford PharmaGenesis is proud to become a Platinum sponsor of HIFA in this important collaboration with the WHO. The aims of the consultation, to promote reliable healthcare information and improve patient lives, are closely aligned with those of our own Open Pharma initiative, which works to increase transparency and access to research outputs.”
“We look forward to keeping in touch with the HIFA-WHO consultation as it progresses, and hope for a successful outcome, which will help to put an end to harmful misinformation, and improve countless patients’ lives.”
